Hyphens Pharma International Limited: Key Insights from Annual Report 2025 Shareholder Q&A

Hyphens Pharma International Limited (HPIL) has released its responses to substantial and relevant questions submitted by shareholders ahead of its Annual General Meeting (AGM) scheduled for 28 April 2026. The responses provide deep insights into HPIL’s current business strategies, operational challenges, growth prospects, and risk management. Investors should pay close attention to several points that may have implications for HPIL’s share price and future direction.

1. Potential Mainboard Listing

The company has indicated it is actively evaluating a potential transfer to the Mainboard of the Singapore Exchange. This move is contingent on meeting listing requirements and favorable market conditions. Such a transfer would likely enhance liquidity and visibility, potentially boosting shareholder value if material developments occur.

2. Geopolitical and Supply Chain Risks

Despite the closure of the Strait of Hormuz and ongoing geopolitical tensions, HPIL has not experienced material financial impact or operational disruptions. However, the company is facing increased freight costs, longer order lead times, and heightened uncertainty in its supply chain. Prolonged geopolitical instability and inflationary pressures could affect overall market demand, especially in regions where HPIL operates.

3. Regulatory Approvals and New Product Launches

Two key products, Wynzora and Amenalief, are advancing through regulatory approval and commercial preparation in selected markets. Sales will commence post-approval and market readiness. Investors should monitor these launches as they may drive growth in the coming periods.

4. Employee Turnover and Profitability Concerns

HPIL has reported employee turnover rates exceeding 20% since 2021, with a stable 25% from 2023 to 2025. Despite concerns about operational efficiency, management attributes turnover to business expansion and organizational adjustments, asserting no material disruption. Notably, net profit has only surpassed \$10 million in two years (FY2022 and FY2024), which may position HPIL as a slow-growth/dividend stock rather than a high-growth one. The company remains committed to long-term growth, emphasizing investment in brand equity, portfolio expansion, and operational efficiency to target higher net profit brackets (\$10m-\$20m annually).

5. Acquisitions and Market Expansion

Acquisitions such as Novem and Ardence Pharma have contributed positively, particularly in the medical aesthetics segment. Singapore and Malaysia are expected to remain key markets, with initial momentum observed in the Philippines, Indonesia, and Thailand. HPIL is selectively shifting away from lower-margin products and markets, optimizing its portfolio for profitability.

6. Product Performance – Nabota

Nabota, launched in Malaysia and Singapore in 2023, has shown positive sales momentum. While still in early commercialization, its absolute contribution remains small. Management is confident about its growth prospects, though no specific figures were disclosed due to confidentiality. This could be a future growth driver if market adoption accelerates.

7. Board Competency and Governance

The Board has recently reviewed its competency matrix and believes it possesses the necessary skills for HPIL’s current operations and growth strategy. The company was awarded Gold for The Best Managed Board at the Singapore Corporate Awards 2024, underscoring strong governance. The Board is prepared to strengthen competencies further as HPIL scales up and potentially qualifies for Mainboard listing.

8. Inventory Management and Regulatory Risks

HPIL has enhanced inventory management processes to reduce write-downs and obsolescence risks. The company faced softer sales in Vietnam due to heightened regulatory enforcement, including stricter Good Pharmacy Practice (GPP) requirements and tighter controls on product registration and distribution channels. No material adverse impact from healthcare policy changes in Singapore, Malaysia, or Vietnam is expected at this time.

9. Proprietary Brands and Marketing Strategy

Despite year-over-year revenue improvements, EBITDA margin in the Proprietary Brands segment contracted due to overhead cost allocations. Ceradan®, HPIL’s flagship dermatological brand, is expanding into the Middle East, but sales in the region remain limited due to evolving market conditions and commercial considerations. The company is evaluating the commercial arrangement with its partner, Cooper Pharma.

HPIL’s skincare brands focus on credibility with healthcare professionals rather than aggressive consumer marketing. However, as the portfolio grows, management recognizes the need to strengthen consumer awareness and may selectively increase consumer-facing initiatives.

10. Insurance Coverage and War Risk

HPIL’s shipments are generally covered by cargo insurance under standard industry terms, but the company does not ship to or operate in active war zones, limiting direct exposure to war-related risks.

11. Digital Platform and E-Pharmacy Challenges

The Digital Platform and E-Pharmacy segment, including DocMed Technology, continues to face profitability challenges amid a highly competitive environment. The primary investment phase is largely complete, and HPIL is now focusing on unlocking value and improving operational efficiency. Management will recalibrate its strategy if the segment fails to meet strategic and financial objectives.
HPIL has begun deploying AI features (e.g., e-MSL module for healthcare professional engagement) but remains measured in its approach, viewing AI as an enabler rather than a primary growth driver.

12. Other Price-Sensitive Information

• Portfolio Optimization: The shift away from lower-margin products has had minimal impact on gross profit, but may signal future revenue and margin improvements.
• Market Entry Challenges: Commercial arrangements in the Middle East for Ceradan® are under review, with market entry proceeding slower than anticipated.
• Future Growth Confidence: Management is confident in achieving sustainable net profit growth over time, supported by proprietary brand expansion, higher-margin portfolios, and operational improvements.

Conclusion: Investment Implications

While HPIL faces ongoing challenges such as high employee turnover, regulatory hurdles, and digital platform profitability, its strategic focus on proprietary brands, market expansion, and operational efficiency positions the company for sustainable growth. Potential Mainboard listing, new product launches, and successful market entry in high-growth regions could serve as catalysts for share price appreciation.

Investors should monitor developments around regulatory approvals, acquisition integration, and the company’s ability to deliver on profitability targets, as these factors will likely influence HPIL’s future valuation.

Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions based on the information provided above. All forward-looking statements are subject to risks and uncertainties.

View Hyphens Pharma Historical chart here